Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
Healthcare
$25.91 +1.84%
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
52W Low $2.15High $28.44
Volume 0.99M
Average 0.34M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$66.36M
FY 2025 · Annual
Net Income
-$63.24M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 210K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 145K | 342K | 0 | 502K | 661K |
| Gross Profit | 65K | (342K) | 0 | (502K) | (661K) |
| Gross Margin | 31.0% | — | — | — | — |
| Research & Development | 8.37M | 23.69M | 30.29M | 47M | 45.62M |
| Selling, General & Admin | 3.75M | 5.16M | 7.52M | 21.61M | 20.75M |
| Operating Expenses | 12.12M | 28.85M | 37.81M | 68.11M | 65.7M |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| EBITDA | (9.04M) | (27.37M) | (34.56M) | (62.3M) | (60.11M) |
| EBITDA Margin | -4305.7% | — | — | — | — |
| Operating Income | (12.06M) | (29.19M) | (37.81M) | (68.61M) | (66.36M) |
| Operating Margin | -5741.0% | — | — | — | — |
| Interest Income | 2K | 114K | 2.35M | 8.85M | 6.6M |
| Interest Expense | 0 | 0 | 1.37M | (1.38M) | 2.47M |
| Other Income / Expenses | 2.87M | 1.48M | 1.5M | 7.18M | 3.13M |
| Income Before Tax | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Pre-Tax Margin | -4374.8% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Net Margin | -4374.8% | — | — | — | — |
| EPS (Basic) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| EPS (Diluted) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| 25.57M | 25.57M | 26.88M | 24.6M | 28.85M | |
| 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
ANRO Earnings Waterfall · TTM
NYSE:ANRO · Revenue to Net Income
Key Ratios
EPS$-2.48
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$74.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.48, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 |
How much revenue does ANRO generate?
Alto Neuroscience, Inc. (ANRO) reported $0.00 of revenue in fiscal 2025.
Is ANRO profitable?
Alto Neuroscience, Inc. (ANRO) reported -$63.24M of net income.
Continue the stock analysis
Jump to another research area for this company.